Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients

Cancer Causes and Control

Volumn 27, Issue 2, 2016, Pages 165-174

  Hvid, Thine ^a   Lindegaard, Birgitte ^a   Winding, Kamilla ^a   Iversen, Peter ^b   Brasso, Klaus ^b   Solomon, Thomas P J ^a,c   Pedersen, Bente K ^a   Hojman, Pernille ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Exercise; Insulin sensitivity and body composition; PSA; PSA doubling time

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TESTOSTERONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

AGED; ANALYTICAL PARAMETERS; ARTICLE; BIOCHEMICAL RECURRENCE; BODY COMPOSITION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SURVEILLANCE; ENDURANCE TRAINING; FITNESS; GLUCOSE BLOOD LEVEL; HOME PHYSIOTHERAPY; HUMAN; IMMUNOLOGICAL PARAMETERS; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; MATSUDA INDEX; OUTPATIENT DEPARTMENT; OXYGEN CONSUMPTION; PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION; BLOOD; ENDURANCE; EXERCISE TEST; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; KINESIOTHERAPY; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADIPONECTIN; AGED; BODY COMPOSITION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DISEASE PROGRESSION; EXERCISE TEST; EXERCISE THERAPY; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEOPLASM RECURRENCE, LOCAL; OXYGEN CONSUMPTION; PHYSICAL ENDURANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958182243     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0694-1     Document Type: Article

References (30)

1. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM (2011) Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 71(11):3889–3895
2. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM (2011) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29(6):726–732
3. Payton S (2013) Prostate cancer: optimizing exercise interventions for men on ADT. Nat Rev Urol 10(11):615
4. Culos-Reed SN, Robinson JW, Lau H et al (2010) Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer 18(5):591–599
5. Segal RJ, Reid RD, Courneya KS et al (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21(9):1653–1659
6. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2):340–347
7. Hvid T, Winding K, Rinnov A et al (2013) Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr Relat Cancer 20(5):621–632
8. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–1470
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419
10. Ornish D, Weidner G, Fair WR et al (2005) Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174(3):1065–1069
11. Frattaroli J, Weidner G, Dnistrian AM et al (2008) Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. Urology 72(6):1319–1323
12. Hebert JR, Hurley TG, Harmon BE, Heiney S, Hebert CJ, Steck SE (2012) A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer. Cancer Epidemiol 36(2):e128–e136
13. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76(6):576–581
14. Klotz L (2006) Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24(1):46–50
15. Thomsen FB, Brasso K, Klotz L, Røder MA, Berg KD, Iversen P (2014) Active surveillance for clinically localized prostate cancer—a systematic review. J Surg Oncol 109(8):830–835
16. Thomsen FB, Christensen IJ, Brasso K, Røder MA, Iversen P (2014) Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. BJU Int 113(5b):E98–E105
17. McTiernan A (2008) Mechanisms linking physical activity with cancer. Nat Rev Cancer 8(3):205–211
18. Baxter RC (2014) IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 14(5):329–341
19. Ornish D, Lin J, Chan JM et al (2013) Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol 14(11):1112–1120
20. Park S, Kim TN, Nam J et al (2012) Recovery of overall exercise ability, quality of life, and continence after 12 week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomised controlled study. Urology 80:299–305
21. Zopf EM, Bloch W, Machtens S, et al (2015) Effects of a 15-months supervised exercise program on physical and psychological outcomes in prostate cancer patients following prostatectomy: the ProReHab study. Intergr Cancer Ther 14(5):409–418
22. Gardner JR, Livingston PM, Fraser SF (2014) Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32(4):335–346
23. Lakoski SG, Eves ND, Douglas PS, Jones LW (2012) Exercise rehabilitation in patients with cancer. Nat Rev Clin Oncol 9(5):288–296
24. Loprinzi PD, Kohli M (2013) Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003–2006. Mayo Clin Proc 88(1):11–21
25. Burton AJ, Martin RM, Donovan JL et al (2012) Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. Cancer Epidemiol Biomark Prev 21(10):1877–1885
26. Rundqvist H, Augsten M, Strømberg A et al (2013) Effect of acute exercise on prostate cancer cell growth. PLoS ONE 8(7):e67579
27. Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P (2014) Muscle dysfunction in cancer patients. Ann Oncol 25(5):947–958
28. Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 4(4):486–501
29. Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97
30. Joshu CE, Mondul AM, Menke A et al (2011) Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res 4(4):544–551